Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b

Archives of Neurology

Volumn 54, Issue 9, 1997, Pages 1169-1170

  Schwid, Steven R ^a,b   Goodman, Andrew D ^a   Mattson, David H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Box 605 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; LEVOTHYROXINE; MICROSOME ANTIBODY; PROPRANOLOL; RADIOACTIVE IODINE; RECOMBINANT BETA INTERFERON; THIAMAZOLE; THYROGLOBULIN ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNITY; CASE REPORT; CLINICAL FEATURE; ETIOLOGY; FEMALE; HUMAN; HYPERTHYROIDISM; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0030876399     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550210095020     Document Type: Article

References (13)

1. Weinstock-Gutmann B, Ransohott RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol. 1995:37:7-15.
2. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnasbn BGW, Burks JS. Management of patients receiving interferon-β1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46:12-18.
3. DeKeyser J. Autoimmunity in multiple sclerosis. Neurology. 1988:38:371-374.
4. Earned S, Goodman AD, Mattson DH. Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology. 1995:45:384-385.
5. Kiessling WR, Pflughaupt KW. Antithyroid antibodies in multiple sclerosis. Lancet. 1980;1:41.
6. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994;10:115-150.
7. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factors for development of thyroid disease during interteron-α therapy for chronic hepatitis C. Am J Gastroenterol. 1994:89:399-403.
8. Rep MH, Hinten RQ, Polman CH, van Lier RA. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol. 1996:67:111-118.
9. Aman MJ, Tretter T, Eisenbeis I, et al. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ Tcells and monocytes. Blood. 1996:87:4731 -4736.
10. Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. JExpMed. 1995:181:839-844.
11. Carella C, Amato G, Biondi B, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy f or HCV chronic hepatitis. Horm Res. 1995:44:110-114.
12. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon-α. Gastroenterology. 1992:102:2155-2160.
13. Baudin E, Marcellin P, Pouteau M, et al. Reversibility of thyroid dysfunction induced by recombinant alpha Interferon in chronic hepatitis C. Clin Endocrinol. 1993:39:657-661.